OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors
Elham Beyranvand Nejad, Camilla Labrie, Marit J. van Elsas, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 4, pp. e002460-e002460
Open Access | Times Cited: 29
Elham Beyranvand Nejad, Camilla Labrie, Marit J. van Elsas, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 4, pp. e002460-e002460
Open Access | Times Cited: 29
Showing 1-25 of 29 citing articles:
Interleukin-6 (IL-6)-associated tumor microenvironment remodelling and cancer immunotherapy
Songsong Wu, Zhumin Cao, Ruinan Lu, et al.
Cytokine & Growth Factor Reviews (2025)
Closed Access | Times Cited: 2
Songsong Wu, Zhumin Cao, Ruinan Lu, et al.
Cytokine & Growth Factor Reviews (2025)
Closed Access | Times Cited: 2
Role of IL-6 in the commitment of T cell subsets
Thomas Korn, Michael Hiltensperger
Cytokine (2021) Vol. 146, pp. 155654-155654
Open Access | Times Cited: 78
Thomas Korn, Michael Hiltensperger
Cytokine (2021) Vol. 146, pp. 155654-155654
Open Access | Times Cited: 78
Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma
Bruno Almeida Costa, Jessica Flynn, Noriko Nishimura, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 8
Bruno Almeida Costa, Jessica Flynn, Noriko Nishimura, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 8
Roles for macrophage-polarizing interleukins in cancer immunity and immunotherapy
Keywan Mortezaee, Jamal Majidpoor
Cellular Oncology (2022) Vol. 45, Iss. 3, pp. 333-353
Closed Access | Times Cited: 37
Keywan Mortezaee, Jamal Majidpoor
Cellular Oncology (2022) Vol. 45, Iss. 3, pp. 333-353
Closed Access | Times Cited: 37
Biomimetic “Gemini nanoimmunoregulators” orchestrated for boosted photoimmunotherapy by spatiotemporally modulating PD-L1 and tumor-associated macrophages
Honglin Huang, Ningxi Li, Xiaodan Wei, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 14, Iss. 3, pp. 1345-1361
Open Access | Times Cited: 15
Honglin Huang, Ningxi Li, Xiaodan Wei, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 14, Iss. 3, pp. 1345-1361
Open Access | Times Cited: 15
Tumour-associated macrophages: versatile players in the tumour microenvironment
Zoey Zeyuan Ji, Max Kam‐Kwan Chan, Alex Siu Wing Chan, et al.
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 11
Zoey Zeyuan Ji, Max Kam‐Kwan Chan, Alex Siu Wing Chan, et al.
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 11
Cancer-associated fibroblasts shape early myeloid cell response to chemotherapy-induced immunogenic signals in next generation tumor organoid cultures
Julijan Kabiljo, A Theophil, J Homola, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 11, pp. e009494-e009494
Open Access | Times Cited: 4
Julijan Kabiljo, A Theophil, J Homola, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 11, pp. e009494-e009494
Open Access | Times Cited: 4
IL-2-loaded liposomes modified with sorafenib derivative exert a synergistic anti-melanoma effect via improving tumor immune microenvironment and enhancing antiangiogenic activity
Xuan Huang, Kudelaidi Kuerban, J P Fan, et al.
Asian Journal of Pharmaceutical Sciences (2025), pp. 101020-101020
Open Access
Xuan Huang, Kudelaidi Kuerban, J P Fan, et al.
Asian Journal of Pharmaceutical Sciences (2025), pp. 101020-101020
Open Access
Exploring Interleukin-6 Inhibitor Antibodies in Combatting SARS-CoV-2 and Its Mutated Variants: Challenges and Future Directions
Mohammed Ali Bakkari, Gassem Ghoal, Fahad Y. Sabei, et al.
Journal of Pharmacology and Pharmacotherapeutics (2025)
Open Access
Mohammed Ali Bakkari, Gassem Ghoal, Fahad Y. Sabei, et al.
Journal of Pharmacology and Pharmacotherapeutics (2025)
Open Access
Unraveling the triad of immunotherapy, tumor microenvironment, and skeletal muscle biomechanics in oncology
Shuang Ma, Ying Lü, S.J. Sui, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Shuang Ma, Ying Lü, S.J. Sui, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
C-reactive protein kinetics as prognostic biomarkers in advanced melanoma treated with immune checkpoint inhibitors
Caner Acar, Haydar Çağatay Yüksel, Gökhan Şahin, et al.
Melanoma Research (2025)
Closed Access
Caner Acar, Haydar Çağatay Yüksel, Gökhan Şahin, et al.
Melanoma Research (2025)
Closed Access
A novel immune checkpoint siglec-15 antibody inhibits LUAD by modulating mφ polarization in TME
Xuejun Xiao, Yan Peng, Zheyue Wang, et al.
Pharmacological Research (2022) Vol. 181, pp. 106269-106269
Open Access | Times Cited: 17
Xuejun Xiao, Yan Peng, Zheyue Wang, et al.
Pharmacological Research (2022) Vol. 181, pp. 106269-106269
Open Access | Times Cited: 17
Myeloid effector cells in cancer
Pieter J. Schol, Marit J. van Elsas, Jim Middelburg, et al.
Cancer Cell (2024) Vol. 42, Iss. 12, pp. 1997-2014
Closed Access | Times Cited: 3
Pieter J. Schol, Marit J. van Elsas, Jim Middelburg, et al.
Cancer Cell (2024) Vol. 42, Iss. 12, pp. 1997-2014
Closed Access | Times Cited: 3
IL-6-Derived Autocrine Lactate Promotes Immune Escape of Uveal Melanoma
Chaoju Gong, Meiling Yang, Huirong Long, et al.
Investigative Ophthalmology & Visual Science (2024) Vol. 65, Iss. 3, pp. 37-37
Open Access | Times Cited: 2
Chaoju Gong, Meiling Yang, Huirong Long, et al.
Investigative Ophthalmology & Visual Science (2024) Vol. 65, Iss. 3, pp. 37-37
Open Access | Times Cited: 2
Emergency myelopoiesis in solid cancers
Konstantinos Aliazis, Sasitorn Yenyuwadee, Ployploen Phikulsod, et al.
British Journal of Haematology (2024) Vol. 205, Iss. 3, pp. 798-811
Closed Access | Times Cited: 2
Konstantinos Aliazis, Sasitorn Yenyuwadee, Ployploen Phikulsod, et al.
British Journal of Haematology (2024) Vol. 205, Iss. 3, pp. 798-811
Closed Access | Times Cited: 2
Impact of C-reactive Protein Flare Response in Patients With Advanced Urothelial Carcinoma Who Received Pembrolizumab
Ikko Tomisaki, Mirii Harada, Kei Tokutsu, et al.
In Vivo (2021) Vol. 35, Iss. 6, pp. 3563-3568
Open Access | Times Cited: 12
Ikko Tomisaki, Mirii Harada, Kei Tokutsu, et al.
In Vivo (2021) Vol. 35, Iss. 6, pp. 3563-3568
Open Access | Times Cited: 12
A New IL-6 Inducing Mechanism in Cancer with new Therapeutic Possibilities
Leif Håkansson, Pontus Dunér, Erik Broströmer, et al.
(2024)
Open Access | Times Cited: 1
Leif Håkansson, Pontus Dunér, Erik Broströmer, et al.
(2024)
Open Access | Times Cited: 1
The antitumor activity of TGFβ-specific T cells is dependent on IL-6 signaling
Maria Perez-Penco, Mikkel Byrdal, Lucía Lara de la Torre, et al.
Cellular and Molecular Immunology (2024)
Open Access | Times Cited: 1
Maria Perez-Penco, Mikkel Byrdal, Lucía Lara de la Torre, et al.
Cellular and Molecular Immunology (2024)
Open Access | Times Cited: 1
Exploration of the effect of Celastrol on protein targets in nasopharyngeal carcinoma: Network pharmacology, molecular docking and experimental evaluations
Junjun Ling, Yu Huang, Zhen Sun, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 4
Junjun Ling, Yu Huang, Zhen Sun, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 4
Differentially polarized macrophages show diverse proangiogenic characteristics under normo- and hyperglycemic conditions
Mahnaz Shariatzadeh, César Payán‐Gómez, Willem A. Dik, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Mahnaz Shariatzadeh, César Payán‐Gómez, Willem A. Dik, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
In vitro T cell responses to PD-1 blockade are reduced by IFN-α but do not predict therapy response in melanoma patients
Laura M. Timmerman, Lobke C.M. Hensen, Mick J M van Eijs, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 9
Open Access
Laura M. Timmerman, Lobke C.M. Hensen, Mick J M van Eijs, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 9
Open Access
Dual-responsive natural killer cell nano-engagers for cancer immunotherapy via inhibiting IL-6/JAK2/STAT3 pathway
Xiangrui Meng, Zhan Xue, Hang Xiao, et al.
Chemical Engineering Journal (2024) Vol. 499, pp. 156423-156423
Closed Access
Xiangrui Meng, Zhan Xue, Hang Xiao, et al.
Chemical Engineering Journal (2024) Vol. 499, pp. 156423-156423
Closed Access
A New IL-6-Inducing Mechanism in Cancer with New Therapeutic Possibilities
Leif Håkansson, Pontus Dunér, Erik Broströmer, et al.
Cancers (2024) Vol. 16, Iss. 21, pp. 3588-3588
Open Access
Leif Håkansson, Pontus Dunér, Erik Broströmer, et al.
Cancers (2024) Vol. 16, Iss. 21, pp. 3588-3588
Open Access
Tumor-associated inflammation: the role and research progress in tumor therapy
Jingxia Xu, Xiaoman Xu, Huiwen Zhang, et al.
Journal of Drug Delivery Science and Technology (2024) Vol. 102, pp. 106376-106376
Closed Access
Jingxia Xu, Xiaoman Xu, Huiwen Zhang, et al.
Journal of Drug Delivery Science and Technology (2024) Vol. 102, pp. 106376-106376
Closed Access
Research Progress on the Relationship between IL-6 and the Treatment and Prognosis of Colorectal Cancer
晓倩 边
Advances in Clinical Medicine (2023) Vol. 13, Iss. 02, pp. 2581-2587
Closed Access
晓倩 边
Advances in Clinical Medicine (2023) Vol. 13, Iss. 02, pp. 2581-2587
Closed Access
